- Home
- REFI vs ALDX Comparison
REFI vs ALDX Comparison
Compare REFI & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- ALDX
- Stock Information
- Founded
- REFI 2021
- ALDX 2004
- Country
- REFI United States
- ALDX United States
- Employees
- REFI N/A
- ALDX N/A
- Industry
- REFI Real Estate Investment Trusts
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- ALDX Health Care
- Exchange
- REFI Nasdaq
- ALDX Nasdaq
- Market Cap
- REFI 314.2M
- ALDX 304.9M
- IPO Year
- REFI 2021
- ALDX 2014
- Fundamental
- Price
- REFI $15.31
- ALDX $6.91
- Analyst Decision
- REFI Strong Buy
- ALDX Strong Buy
- Analyst Count
- REFI 3
- ALDX 2
- Target Price
- REFI $20.00
- ALDX $10.00
- AVG Volume (30 Days)
- REFI 180.1K
- ALDX 636.8K
- Earning Date
- REFI 03-12-2025
- ALDX 05-01-2025
- Dividend Yield
- REFI 16.98%
- ALDX N/A
- EPS Growth
- REFI N/A
- ALDX N/A
- EPS
- REFI 1.88
- ALDX N/A
- Revenue
- REFI $55,534,183.00
- ALDX N/A
- Revenue This Year
- REFI N/A
- ALDX N/A
- Revenue Next Year
- REFI N/A
- ALDX N/A
- P/E Ratio
- REFI $8.14
- ALDX N/A
- Revenue Growth
- REFI N/A
- ALDX N/A
- 52 Week Low
- REFI $14.82
- ALDX $2.71
- 52 Week High
- REFI $16.47
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- REFI 35.29
- ALDX 61.80
- Support Level
- REFI $15.97
- ALDX $6.79
- Resistance Level
- REFI $16.15
- ALDX $7.20
- Average True Range (ATR)
- REFI 0.28
- ALDX 0.56
- MACD
- REFI -0.11
- ALDX 0.03
- Stochastic Oscillator
- REFI 19.33
- ALDX 88.02
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.